Using immunohistochemistry, we also found that all patients with a negative TPS of PD-L1 in tumour cells were nonresponders (Fig. 7e), further proving that downregulated PD-L1 expression contributes to immunotherapy resistance. Here, CD274 is linked to neoplasm.